Clinical trials using PARP inhibitors for breast cancer with germline BRCA1/2 mutations have shown promising results in the neoadjuvant [99] and metastatic setting [100,101], and are being actively studied in TNBC with HRDs [102]. The gene discussed is BRCA1; the disease is breast cancer.